Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.
Clin Pharmacol Ther. 2010 Nov;88(5):685-94. doi: 10.1038/clpt.2010.176. Epub 2010 Sep 15.
The impact of thyroid dysfunction on the regulation, expression, and function of ABCB1 remains unclear. We therefore investigated ABCB1 mRNA expression and function in patients with thyroid dysfunction and studied the disposition of the ABCB1 substrate digoxin before and after treatment for thyroid disease. In patients with hypothyroidism, normalization of thyroid function was associated with a 1.8-fold increase in mRNA expression and a 26% increase in rhodamine efflux from CD56(+) cells. In hypothyroidism, digoxin clearance was significantly decreased, whereas bioavailability, volume of distribution, half-life time, and protein binding were unaltered. In hyperthyroidism, ABCB1 mRNA expression, rhodamine efflux, and disposition of digoxin were not significantly affected other than in relation to renal clearance. Experiments using the LS174T cell line indicated that the gene is a direct target of thyroid hormone receptors. In conclusion, thyroid abnormalities can exert significant effects on the expression of P-glycoprotein, thereby altering the disposition and action of drugs that are substrates of P-glycoprotein.
甲状腺功能障碍对 ABCB1 的调节、表达和功能的影响尚不清楚。因此,我们研究了甲状腺功能障碍患者的 ABCB1 mRNA 表达和功能,并研究了甲状腺疾病治疗前后 ABCB1 底物地高辛的处置情况。在甲状腺功能减退症患者中,甲状腺功能正常化与 mRNA 表达增加 1.8 倍和 CD56(+)细胞中罗丹明外排增加 26%相关。在甲状腺功能减退症中,地高辛清除率显著降低,而生物利用度、分布容积、半衰期和蛋白结合率则没有改变。在甲状腺功能亢进症中,除了与肾清除率有关外,ABCB1 mRNA 表达、罗丹明外排和地高辛处置均不受影响。使用 LS174T 细胞系的实验表明,该基因是甲状腺激素受体的直接靶标。总之,甲状腺异常可对 P-糖蛋白的表达产生显著影响,从而改变 P-糖蛋白底物药物的处置和作用。